Detailed data surrounding antimicrobial usage in patients with coronavirus disease 2019 (COVID-19) are lacking. To date, our institution has not been an epicenter of the pandemic. Thus, the slow but consistent flow of cases has allowed for careful consideration of each case for candidacy for clinical trial enrollment, and formal infectious diseases consultation is provided for all inpatient encounters. Despite low local prevalence at the time, we found a cursory review of antibiotic prescribing early in the pandemic to be imperative, setting the stage for adjustment of antimicrobial stewardship practices if a future surge is to be observed. As we enter further into the realm of the unknown, data continue to emerge outlining indirect outcomes of COVID-19. One such outcome is the rate of coinfection with other pathogens and the associated use of antimicrobials. (1) Currently, data are sparse concerning antimicrobial management strategies for COVID-19. One review posited that coinfection during COVID-19 is rare; however, antimicrobial use among inpatients is common. (2) Some organizations have published guidelines to help streamline antimicrobial use in patients with pneumonia during the COVID-19 pandemic. (3) Despite the acute COVID-19 pandemic, antimicrobial resistance continues to be an ongoing and silent epidemic, accounting for \~3 million cases and \~35,000 deaths annually. (4) As the pandemic evolves, consideration should be given to evaluating the impact of potential excessive and/or unnecessary antimicrobial use in COVID-19 patients to mitigate unintended consequences, including adverse effects, unnecessary cost, and antimicrobial resistance.

Methods {#s1}
=======

We retrospectively evaluated local patients diagnosed with COVID-19 at our large, academic, tertiary-care center during an inpatient, emergency department (ED), or outpatient encounter to analyze the prevalence, number of agents, spectrum of activity, and duration of antimicrobial therapy. We included patients ≥18 years of age with a confirmed case of COVID-19 (ie, a positive real-time polymerase chain reaction \[RT-PCR\] assay for severe acute respiratory coronavirus virus 2 \[SARS-CoV-2\]) diagnosed locally between March 1 and April 28, 2020. Only local patients were included to maintain uniformity of practice and review and to better understand local prescribing practices. Patients were excluded if they had not given consent for data utilization through the Minnesota research authorization. Patients were identified with a report of positive RT-PCR generated from the electronic health record. Patients were assigned to groups according to the encounter type during which they were diagnosed with COVID-19 (ie, inpatient, ED, or outpatient).

Given a significant mismatch in patient distribution across encounter types, we opted to describe our findings with descriptive statistics. From individual chart reviews, we evaluated patient demographics, risk factors, prevalence and result of other diagnostic testing (ie, respiratory cultures, respiratory virus pathogen panels \[RVPs\], or influenza testing), and disease severity. Mild disease was defined as no additional oxygen requirement, moderate disease as new or increased need for supplemental oxygen, and severe disease as need for invasive or noninvasive ventilation or intensive care unit (ICU) admission. Risk factors for outpatients and inpatients were obtained from the problem list and inpatient notes, respectively.

Antimicrobial prescribing data were included when employed for a suspected or confirmed respiratory tract infection. Antimicrobial utilization was evaluated by overall prescribing rate, days of therapy (DOT), DOT per antimicrobial day, and duration of therapy. Inpatients discharged on oral antimicrobials were included in overall antimicrobial metrics. For patients managed in ED or outpatient encounters, antimicrobials prescribed for a respiratory indication within 14 days of the testing date were reported. To provide assessment of the antimicrobial spectrum across various encounter types, an antimicrobial spectrum score developed by Gerber et al^[@r5]^ was applied to antimicrobial use data. Total spectrum scores were calculated and normalized by duration of therapy to determine the antimicrobial spectrum score per total antimicrobial day.

Table 1.Population DemographicsCharacteristicsFull Cohort\
(n = 346), %^[a](#t1fn1){ref-type="table-fn"}^Inpatient, %^[a](#t1fn1){ref-type="table-fn"}^Ambulatory, %^[a](#t1fn1){ref-type="table-fn"}^All\
(n = 39)Mild\
(n = 7)Moderate (n = 17)Severe\
(n = 15)All\
(n = 307)Emergency Department\
(n = 20)Outpatient Encounter\
(n = 287)Age, mean y ±SD45 ± 1859 ± 1942 ± 1666 ± 1458 ± 2044 ± 1751 ± 1943 ± 17Male494629475349.55549Mean Charlson comorbidity index ± SD2 ± 34 ± 43 ± 44 ± 44 ± 32 ± 32 ± 32 ± 3Length of stay, mean d ±SDN/A8.5 ± 52.6 ± 0.79.1 ± 4.711.5 ± 3.5N/AN/AN/A**Risk factors**Nursing home bound230072102Diabetes153114412721013Hypertension182303520183017Heart failure31302472151Hyperlipidemia161802913151016Obesity2136143547191019Malignancy315141220252Lung disease81802420708Age \>65 y10361453277256CKD31314187252Immunocompromising condition35067303No risk factors53237112125750571--2 risk factors30331424533025303--5 risk factors1538145333122511\>5 risk factors250120101Note. N/A, not available; SD, standard deviation; CKD, chronic kidney disease.[^1]

Table 2.Antimicrobial UtilizationAntimicrobial MetricFull Cohort\
(n = 346)InpatientAmbulatoryAll\
(n = 39)Mild\
(n = 7)Moderate\
(n = 17)Severe\
(n = 15)All\
(n = 307)Emergency Department\
(n = 20)Outpatient Encounter\
(n = 287)Antibiotics Rx, no. (%)33 (10)23 (59)2 (29)8 (47)13 (87)10 (3)3 (15)7 (2)Duration, mean d ±SD5.7 ± 2.75.4 ± 2.95.5 ± 4.53.5 ± 2.76.5 ± 2.36.3 ± 2.16.8 ± 2.06.0 ± 2.0Mean spectrum score per antimicrobial day ± SD8.0 ± 3.59.2 ± 3.28.1 ± 7.08.4 ± 1.59.9 ± 2.74.9 ± 2.05.5 ± 2.34.4 ± 1.6Total DOT/antimicrobial days1.591.651.181.291.841.351.191.5Total DOT2872051336156773245Ceftriaxone DOT535301241000Cefdinir DOT200000201010Cefazolin DOT22200000Azithromycin DOT744411330301020Doxycycline DOT1510019505Vancomycin DOT26262222000Piperacillin/Tazobactam DOT28280820000Cefepime DOT31311030000Metronidazole DOT22002000Amoxicillin DOT50000550Amoxicillin/Clavulanate DOT00000000Penicillin DOT10000010010Cefuroxime DOT22002000Cefadroxil DOT77700000Levofloxacin DOT125050770Note. SD, standard deviation; Rx, prescription; DOT, days of therapy.

Results {#s2}
=======

In total, 346 patients met inclusion criteria (Table [1](#tbl1){ref-type="table"}). The mean age of the total population was 45 years, and 49% were men. Inpatient encounters accounted for 39 patients (11.3%): 7 cases (17.9%) were mild, 17 cases (43.6%) were moderate, and 15 cases (38.5%) were severe. Also, 4 inpatients remained admitted at the time of article submission, with data collected through May 5, 2020. Ambulatory encounters accounted for 307 patients, with 20 (5.8%) diagnosed in the ED and 287 (82.9%) diagnosed as outpatients. All patients diagnosed as outpatients were diagnosed by collection of specimens in a drive-through testing station with follow-up by virtual or telephone encounters. Of all patients initially managed in the ambulatory setting, 25 (8%) had follow-up ED encounters and 12 (4%) were admitted as inpatients before May 5, 2020.

Respiratory cultures were collected from 8 patients, all in the inpatient cohort: 6 were collected by tracheal aspiration and 2 by expectorated sputum. A causative pathogen (methicillin-sensitive *Staphylococcus aureus*) was only identified in 1 culture. Respiratory viral panels were collected in 4 patients and from the entire inpatient cohort, none of which identified a coinfecting pathogen. Influenza testing was performed in 12 inpatients (31%), 2 outpatients (1%), and no patients in the ED cohort. All influenza tests were negative.

Across the entire cohort, 10% of patients received antimicrobial therapy for a mean duration of 5.7 days, with a mean spectrum score per DOT of 8 (Table [2](#tbl2){ref-type="table"}). Antimicrobials were administered in 59% of all inpatients with rates of 29%, 47%, and 87% for mild, moderate, and severe cases, respectively. The average number of DOT per antimicrobial day in all inpatients was 1.65: 1.18 for mild cases, 1.29 for moderate cases, and 1.84 for severe cases, respectively. The mean spectrum score per day of antimicrobial therapy was 9.2 in all inpatients and increased with disease severity, with mean scores per day of therapy of 8.1, 8.4, and 9.9 in mild, moderate, and severe cases, respectively. The mean duration of therapy in inpatients was 5.4 days: 5.5 days for mild cases, 3.5 days for moderate cases, and 6.5 days for severe cases.

Antimicrobial prescribing rates were considerably lower for ambulatory patients (3% overall), with ED and outpatient encounters demonstrating prescribing rates of 15% and 2%, respectively. Ambulatory antimicrobials were prescribed for a mean duration of 6.3 days: 6.8 days for ED encounters and 6 days for outpatient encounters. Ambulatory regimens generally contained fewer antimicrobials (1.35 DOT per antimicrobial day) and appeared to have narrower spectra (mean spectrum score per day of antimicrobial therapy, 4.9) than inpatient regimens. Across all included patients, no prescriptions for oseltamivir were issued.

Discussion {#s3}
==========

During the COVID-19 pandemic, a reasonable amount of apprehension from providers regarding withholding antibiotics is expected, and vigilance by antimicrobial stewardship teams to identify and intervene upon unnecessary or inappropriate use is essential for mitigation of their unintended adverse consequences. The overall incidence of bacterial coinfection in patients with COVID-19 seems to be \~10%, based on various studies emerging from China, Italy, and the United States.^[@r6]--[@r12]^ Despite this fact, the overall rate of antimicrobial usage, especially among inpatients, appears to be high. A review of 18 studies reporting antimicrobial use in patients with COVID-19 found the prescribing rate to be 72%, with no antimicrobial stewardship interventions described in these studies to combat overuse.^[@r2]^ Data demonstrating clinical benefit of antibiotics as part of the routine management of patients with COVID-19 are lacking; retrospective cohort studies report similar or higher rates of antibiotic use in COVID-19 nonsurvivors compared to survivors.^[@r13],[@r14]^

With concerns being raised for a wave of antimicrobial resistance following this pandemic, we sought to evaluate our early inpatient prescribing data to determine whether it correlated with other available reports. We identified similar rates of antimicrobial use in inpatients as seen in other recent studies, and, of unique value, we identified that very few outpatients received antimicrobials when diagnosed with COVID-19. We also found that coinfections with other pathogens were infrequent. Overall, antimicrobials were prescribed in 10% of patients. Inpatient admissions led to a higher prescription rates (59%) compared to ambulatory encounters (3%). We applied a previously described spectrum score to demonstrate the spectrum of antimicrobials used. This score assigns each antimicrobial a numerical score based on its spectrum of activity.^[@r5]^ In our review, when antimicrobials were prescribed, the duration of therapy appeared similar between inpatient and ambulatory encounters, but inpatients tended to receive broader-spectrum agents, as demonstrated by the mean spectrum score per day of antimicrobial therapy (9.2 for inpatients vs 4.9 for outpatients). Among the inpatient cohort, patients with severe disease received the broadest spectrum agents and longest durations of antimicrobials. Among the outpatient cohort, in addition to the relative infrequency of outpatient antimicrobial prescribing, narrower-spectrum antimicrobials were used in comparison to inpatient regimens.

Although comparative data pertaining to outpatient antimicrobial prescribing in COVID-19 patients are not available, our outpatient results represent an important finding, given increased attention to ambulatory antimicrobial stewardship with the new Joint Commission regulatory standards in 2020. Aside from COVID-19, other studies have evaluated antimicrobial prescribing patterns in outpatient settings for respiratory indications unlikely to benefit from antimicrobials and found prescribing rates of \~21%.^[@r15],[@r16]^ Factors that influence inappropriate prescribing of antimicrobials include diagnostic uncertainty, time pressures, and perception of patient pressure antimicrobial prescribing.^[@r17]^ A potential hypothesis for our low rate of antimicrobial prescribing in the outpatient setting is that ambulatory encounters involved cases that were milder, for which the positive RT-PCR provided a level of diagnostic certainty, and for which time-related and patient-driven antibiotic prescribing pressures may have been reduced given virtual or telephone follow-up. Additionally, at our institution, the infectious disease division played an active role in logistical and resource support for managing ambulatory COVID-19 encounters, likely easing provider concerns pertaining to withholding antibiotics. As antimicrobial stewardship teams look to optimize antimicrobial utilization in COVID-19, our findings suggest that efforts should be focused on the inpatient and ED settings. Attempts to further optimize outpatient antimicrobial prescribing in COVID-19 cases, where ID specialists are already actively involved likely represents a scenario in which effort could far exceed the potential impact.

Our study has several limitations. Most importantly, our center is a large academic center in a relatively small community located in an area of low disease prevalence, which may limit external validity. Laboratory studies testing for the presence of coinfection were not employed in all patients. Thus, coinfection rates reported may not represent the absolute rates that may have been observed had testing been widely utilized. Also, these data were collected from patients seen very early on in the pandemic, when information regarding coinfection with bacterial pathogens was sparse.

Detailed data specific to antimicrobial use in patients with COVID-19 across the care continuum are currently limited. When reported, specific antimicrobial utilization metrics are often missing. A pertinent strength of our study is the application of spectrum scoring in addition to other common antimicrobial use metrics. Most importantly, we have described data pertaining to antimicrobial utilization in 287 patients diagnosed and managed as outpatients. An understanding of antimicrobial prescribing rates across the continuum of care, as reported here, will allow facilities to carefully craft targeted antimicrobial stewardship strategies to contribute to the minimization of unnecessary and/or inappropriate antimicrobials in patients with COVID-19.

At our center, increased prescribing rates and broader spectrums of antimicrobial activity seemed to be used in patients with greater disease severity and those requiring a higher level of care. However, increased antimicrobial utilization did not coincide with increased observation of bacterial coinfection. We are reassured to know that inpatient management of nonsevere cases and outpatient management of mild cases did not involve widespread antimicrobial usage. Management of COVID-19 patients must reflect available and evolving evidence. Bacterial coinfection seems to be rare, even more so in areas of low prevalence. Routine use of broad-spectrum agents and long durations of antimicrobials in patients with COVID-19 are likely unnecessary and could contribute to the epidemic of antimicrobial resistance. Larger studies across multiple institutions and geographic regions are needed to further explore this subject and to define optimal antimicrobial stewardship strategies.
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